Comparison between two drugs that which provides longer pain free time after upper limb surgery surgery

Comparative study of 0.5% Ropivacaine plus magnesium sulfate versus 0.5% Ropivacaine plus Dexmedetomidine as an adjuvant in brachial plexus block

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2022/12/048082

Enrollment

Registered

2022-12-13

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: S518- Open wound of forearm Health Condition 2: S529- Unspecified fracture of forearm

Interventions

Intervention1: Comparative study of Ropivacaine plus Dexmedetomidine and Ropivacaine plus magnesium sulfate in brachial plexus block: Patients divided into two groups. 1 group of patients received in

Eligibility

Inclusion criteria

Inclusion criteria: Patients with forearm fracture of ASA PS-I, II, WEIGHT -40Kg to 70 kg to be included in the study

Exclusion criteria

Exclusion criteria: Patient refusal, infection at the site of block, known allergy to the drugs uesd in the study, patients with coagulation disorder

Design outcomes

Primary

Measure	Time frame
Dexmedetomidine provide longer duration of analgesia than magnesium sulfateTimepoint: VAS SCORE will be assessed at base line, 1hr,2hr,4hr,8hr,12hr,18hr,24hr	—

Secondary

Measure	Time frame
Total Rescue analgesia requirement will be less in Dexmedetomidine group than magnesium sulfate groupTimepoint: VAS SCORE at 0hr, 1hr,2hr,4hr,6hr,12hr,24hr to be measured.	—

Countries

India

Contacts

Public ContactSubhashree Sahu

VIMSAR, BURLA

rosysubhashreesahu@gmail.com7655040459

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026